bioRxiv · 10.1101/2024.04.03.588009
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers
Abstract
Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of TP53 with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes BAX and TP53I3 failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue. LFS-BC had lower CD8+ T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from in situ to invasive BC was marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Boruah, N., Hoyos, D., Moses, R., Hausler, R., Desai, H., Le, A. N., Good, M., Kelly, G., Raghavakaimal, A., Tayeb, M., Narasimhamurthy, M., Doucette, A., Gabriel, P., Feldman, M. J., Park, J., Lopez de Rodas Gregorio, M., Schalper, K. A., Goldfarb, S. B., Nayak, A., Levine, A. J., Greenbaum, B. D., Maxwell, K. N.. 2024-04-07. Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers. https://doi.org/10.1101/2024.04.03.588009
Cite the original work for its findings. Save a collection to share your selection of sources.